首页> 外文期刊>Circulation. Arrhythmia and electrophysiology >Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Patient outcomes, incidence of appropriate and inappropriate interventions, and complications
【24h】

Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Patient outcomes, incidence of appropriate and inappropriate interventions, and complications

机译:致心律失常性右心室发育不良/心肌病中的植入式心脏复律除颤器:患者预后,适当和不适当干预措施的发生率以及并发症

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background-Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is a cardiomyopathy characterized by ventricular arrhythmias and an abnormal right ventricle. Implantable cardioverter defibrillator (ICD) therapy may prevent sudden cardiac death in patients with ARVD/C. Currently, an overview of outcomes, appropriate and inappropriate interventions, and complications of ICD therapy in ARVD/C is lacking. Methods and Results-A literature search was performed to identify studies reporting outcome and complications in patients with ARVD/C who underwent ICD implantation. Of 641 articles screened, 24 studies on 18 cohorts were eligible for inclusion. In case of multiple publications on a cohort, the most recent publication was included in the meta-analysis. There were 610 patients (mean age, 40.4 years; 42% women), who had an ICD for primary or secondary prevention of sudden cardiac death. Risk factors for sudden cardiac death were presyncope (61%), syncope (31%), previous cardiac arrest (14%), ventricular tachycardia (58%), and ventricular fibrillation (6%). Antiarrhythmic medication consisted mostly of β-blockers (38%), amiodarone (14%), or sotalol (30%). During the 3.8-year follow-up, annualized cardiac mortality rate was 0.9%, annualized noncardiac mortality rate was 0.8%, and annualized heart transplant rate was 0.9%. The annualized appropriate and inappropriate ICD intervention rates were 9.5% and 3.7%, respectively. ICD-related complications consisted of difficult lead placement (18.4%), lead malfunction (9.8%), infection (1.4%), lead displacement (3.3%), and any complication (20.3%). Conclusions-Cardiac and noncardiac mortality rates after ICD implantation in patients with ARVD/C are low. Appropriate ICD interventions occur at a rate of 9.5%/y. Inappropriate ICD interventions and complications lead to considerable ICDrelated morbidity.
机译:背景-心律失常性右室发育不良/心肌病(ARVD / C)是一种以室性心律不齐和右心室异常为特征的心肌病。植入式心脏复律除颤器(ICD)疗法可预防ARVD / C患者的心源性猝死。目前,缺乏对ARVD / C中ICD治疗的结果,适当和不适当的干预措施以及并发症的概述。方法和结果-进行文献检索以鉴定报告接受ICD植入的ARVD / C患者的结果和并发症的研究。在筛选的641篇文章中,有18个队列的24项研究符合纳入条件。如果一个队列中有多个出版物,则荟萃分析中包括最新出版物。有610例患者(平均年龄40.4岁;女性占42%)接受了ICD来预防心源性猝死的一级或二级预防。心脏猝死的危险因素为晕厥前(61%),晕厥(31%),先前的心脏骤停(14%),室性心动过速(58%)和室颤(6%)。抗心律失常药物主要由β受体阻滞剂(38%),胺碘酮(14%)或索他洛尔(30%)组成。在3.8年的随访期间,年化心脏死亡率为0.9%,年化非心脏死亡率为0.8%,年化心脏移植率为0.9%。适当和不适当的ICD年度干预率分别为9.5%和3.7%。与ICD相关的并发症包括困难的导线放置(18.4%),导线故障(9.8%),感染(1.4%),导线移位(3.3%)和任何并发症(20.3%)。结论ARVD / C患者ICD植入后的心脏和非心脏死亡率较低。适当的ICD干预发生率为9.5%/年。不当的ICD干预和并发症会导致ICD相关的发病率上升。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号